Source: PreveCeutical Medical Inc.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • PreveCeutical Medical (PREV) has signed a licence agreement with its subsidiary PreveCeutical (Australia) Pty (PAPL)
  • The agreement is for the exclusive rights to the Sol-Gel intellectual property and technology for the delivery of cannabinoids
  • This licence agreement provides PreveCeutical the ability to enter into a commercial transaction with a third-party partner in relation to both the PreveCeutical and PAPL intellectual property in preparation for potential commercialization
  • PreveCeutical is a health sciences company that develops options for preventive and curative therapies utilizing organic and nature-identical products
  • PreveCeutical Medical Inc. opened trading at $0.03

PreveCeutical Medical (PREV) has signed a licence agreement with its subsidiary PreveCeutical (Australia) Pty (PAPL)

The agreement is for the exclusive rights to the Sol-Gel intellectual property and technology for the delivery of cannabinoids.

PAPL has an exclusive licence agreement with UniQuest Pty Ltd, the commercialization company of The University of Queensland. This gives PAPL the right to use and sub-license the Sol-Gel technology (patent application AU2020903065 titled “Sol-gel composition”) to deliver naturally occurring cannabinoids and chemically synthesized versions to all regions and membranes of the body, including nasal delivery.

This licence agreement provides PreveCeutical the ability to enter into a commercial transaction with a third-party partner in relation to both the PreveCeutical and PAPL intellectual property in preparation for potential commercialization.

“This intercompany licensing arrangement is a part of the strategic plan for PreveCeutical as it will simplify any potential future commercial transactions as all Sol-Gel Licence-related intellectual properties will be controlled directly by PreveCeutical, the parent company,” stated Stephen Van Deventer, PreveCeutical’s Chief Executive Officer.

“PreveCeutical has been working tirelessly over the last year to ensure that the company is in a good position for potential commercialization,” he added.

With the completion of three of its research programs, the company is actively working on the development, clinical trials, and commercialization of its products. It has filed a number of provisional patent applications to protect intellectual property from its research programs.

PreveCeutical is a health sciences company that develops options for preventive and curative therapies utilizing organic and natural identical products.

PreveCeutical Medical Inc. opened trading at $0.03.


More From The Market Herald
Parkview Project in New World Island, Newfoundland

" Lithium One (TSXV:LONE) expands land position in Northwest Ontario

Lithium One Metals (LONE) has signed an agreement to acquire an additional lithium property.

" Candente Copper (TSX:DNT) Closes Private Placement With Fortescue Metals

Candente Copper (DNT) closes the previously announced private placement with Nascent Exploration Fortescue Metals Group, raising $4,000,000.

" BeWhere (TSXV:BEW) launches BeMini asset tracker on Geotab Marketplace

BeWhere (BEW) announced the launch of its BeMini on Geotab’s Marketplace.

" LithiumBank (TSXV:LBNK) to develop Boardwalk and Park Place lithium brine projects

LithiumBank Resources (LBNK) has released key milestones for its Boardwalk and Park Place lithium projects.